Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

Datasets for IBD: Could they be useful?3rd H-ECCO IBD Masterclass
Year: 2018
Authors: Feakins Roger
Files: 1
Diagnosis, anatomy and physiology in IBD9th N-ECCO School
Year: 2018
Authors: Ferrante Marc
Files: 1
Dietary pathogenesis in Ulcerative Colitis3rd D-ECCO Workshop
Year: 2018
Authors: Sarbagili Chen
Files: 1
Dietary supplements in IBD3rd D-ECCO Workshop
Year: 2018
Authors: Sigall-Boneh Rotem
Files: 1
Does size matter? How long should the Pouch be?7th S-ECCO IBD Masterclass
Year: 2018
Authors: Colombo Francesco
Files: 1
DOP001: Effectiveness and safety of vedolizumab in anti-TNF naïve patients with Inflammatory Bowel Disease - a multicentre retrospective studyECCO'18 Vienna
Year: 2018
Authors: Kopylov Uri
Files: 1
DOP002:Vedolizumab treatment persistence up to 3 years: Post hoc analysis in vedolizumab-naïve patients from the GEMINI LTS studyECCO'18 Vienna
Year: 2018
Authors: Vermeire Séverine
Files: 1
DOP003: Ustekinumab induces clinical and biological remission in biologic refractory Crohn's Disease patients: A real world belgian cohort studyECCO'18 Vienna
Year: 2018
Authors: Liefferinckx Claire
Files: 1
DOP004: Long-term safety of adalimumab in patients with Moderate to Severe Ulcerative Colitis: Interim results of a non-interventional registry, LEGACYECCO'18 Vienna
Year: 2018
Authors: Bossuyt Peter
Files: 1
DOP005: Safety of vedolizumab in patients naïve to treatment with TNF antagonists compared with patients with prior use of TNF antagonistsECCO'18 Vienna
Year: 2018
Authors: Russell Cohen
Files: 1
DOP006: A multicentre cohort study to assess the safety of vedolizumab for Inflammatory Bowel DiseaseECCO'18 Vienna
Year: 2018
Authors: Dulai Parambir S
Files: 1
DOP007: Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha resistant Inflammatory Bowel DiseaseECCO'18 Vienna
Year: 2018
Authors: Bor Renata
Files: 1
DOP008: Safety of adalimumab in children and adolescents with Moderate to Severe Crohn’s Disease: Interim results of the CAPE registryECCO'18 Vienna
Year: 2018
Authors: Turner Dan
Files: 1
DOP009: Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for Inflammatory Bowel Disease: A multicentre consortium propensity score–matched analysisECCO'18 Vienna
Year: 2018
Authors: Dulai Parambir S
Files: 1
DOP011: Genotype-Phenotype association analysis of Inflammatory Bowel Disease in 6,395 East Asian subjects: Results from the international IBD Genetics ConsortiumECCO'18 Vienna
Year: 2018
Authors: Abedian Shifteh
Files: 1
DOP012: Disease demarcation in Ulcerative Colitis is associated with different patterns of gene expressionECCO'18 Vienna
Year: 2018
Authors: Argmann Carmen
Files: 1
DOP013: An IBD associated variant in PTPN2 promotes inflammatory responses but enhances the anti-inflammatory effect of spermidineECCO'18 Vienna
Year: 2018
Authors: Butter Matthias
Files: 1
DOP014: Impact of genetic variation on gene and protein expression in Crohn’s DiseaseECCO'18 Vienna
Year: 2018
Authors: Hart Amy
Files: 1
DOP015: Dysregulation of cell-type specific long ncRNA in the ileum of treatment naïve early onset Crohn DiseaseECCO'18 Vienna
Year: 2018
Authors: Haberman Yael
Files: 1
DOP016: Metagenomic analysis of intestinal mucosa revealed an IBD-specific shift in the eukaryotic gut virome composition at early stages of gut inflammationECCO'18 Vienna
Year: 2018
Authors: Ungaro Federica
Files: 1